222. Primary nephrotic syndrome Clinical trials / Disease details


Clinical trials : 285 Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-003233-38-IT
(EUCTR)
06/04/202104/06/2021A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous NephropathyA PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY - A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropa Primary Membranous Nephropathy (pMN)
MedDRA version: 21.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Gazyvaro
Product Name: Obinutuzumab
Product Code: [RO5072759]
INN or Proposed INN: OBINUTUZUMAB
Other descriptive name: OBINUTUZUMAB/ GA101
Trade Name: Prograf
Product Name: Tacrolimus
Product Code: [RO0485337]
INN or Proposed INN: TACROLIMUS
Trade Name: Prograf
Product Name: Tacrolimus
Product Code: [RO0485337]
INN or Proposed INN: TACROLIMUS
Trade Name: Adoport
Product Name: Tacrolimus
Product Code: [RO0485337]
INN or Proposed INN: TACROLIMUS
Trade Name: Prograf
Product Name: Tacrolimus
Product Code: [RO0485337]
INN or Proposed INN: TACROLIMUS
Trade Name: Adoport
Product Name: Tacrolimus
Product Code: [RO0485337]
INN or Proposed INN: TACROLIMUS
F. HOFFMANN - LA ROCHE LTD.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140Phase 3United States;Spain;Ukraine;Turkey;Israel;Russian Federation;Italy;France;Canada;Argentina;Brazil;Poland;Peru;China